Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Charles D. Ii Goodwin is Chief Executive Officer at Apyx Medical. OQRO lists 1 transaction filed with the SEC under this name, the latest on Jun 15, 2026, each linked to the official Form 4.
Chief Executive Officer
Disclosures on record
1
Companies involved
1
Apyx MedicalAPYX
Jun 11, 2026214Kdisclosed Jun 15
DetailsOfficial recordCharles D. Ii Goodwin bought shares on the open market in 2020, 2022 and 2023, and has not bought since 2023.
Charles D. Ii Goodwin reported 4 open-market purchases and 0 sales since 2020; purchases in 3 different years, most recently 2023.
| Year | Bought | Sold |
|---|---|---|
| 2023 | $79K1×1 trade | — |
| 2022 | $70K2×2 trades | — |
| 2020 | $93K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Charles D. Ii Goodwin reported 4 open-market purchases and 0 sales here, 2020 to 2023.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
Charles D. Ii Goodwin bought shares on the open market in 2020, 2022 and 2023, and has not bought since 2023.
In SEC filings since 2020: the latest open-market purchase is from 2023; no open-market sale is on record.
Apyx Medical (APYX), from 2020 to 2023: 4 purchases and 0 sales.